表紙
市場調査レポート

糖尿病性神経障害性疼痛:パイプライン製品の分析

Diabetic Neuropathic Pain - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 245997
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
糖尿病性神経障害性疼痛:パイプライン製品の分析 Diabetic Neuropathic Pain - Pipeline Review, H2 2016
出版日: 2016年07月27日 ページ情報: 英文 95 Pages
概要

糖尿病性神経障害疼痛は、糖尿病性神経障害に伴う一連の症候群です。通常、下肢 (足・脚) や上肢 (手・腕) など、末梢領域や四肢に発症します。症状は、チクチク感やヒリヒリ感、灼熱感、鋭い痛み、刺すような痛み、激痛などが見られます。治療には、抗鬱薬や抗痙攣薬などが含まれます。

当レポートでは、糖尿病性神経障害性疼痛に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

糖尿病性神経障害性疼痛の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • BioDelivery Sciences International, Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company, Limited
  • Dong-A Socio Group
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Hydra Biosciences, Inc.
  • Immune Pharmaceuticals Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Lohocla Research Corporation
  • Mertiva AB
  • Novaremed
  • Pharmaleads
  • RAPID Pharmaceuticals AG
  • Relmada Therapeutics, Inc.
  • Sphaera Pharma Pvt. Ltd.
  • Theravasc, Inc.

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (amitriptyline + ketamine hydrochloride)
  • (diclofenac sodium + triclocarban)
  • AS-1069562
  • ASP-3662
  • AZD-5213
  • clonidine hydrochloride
  • duloxetine hydrochloride DR
  • E-52862
  • filgrastim
  • GERPOOI
  • GRC-17536
  • HC-030031
  • Kindolor
  • mepivacaine hydrochloride
  • mirogabalin besylate
  • NG2-GAD
  • NRD-135SE1
  • PGN-305
  • PL-37
  • RAP-103
  • RAP-104
  • Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain
  • sodium nitrite SR

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8307IDB

Summary

Global Markets Direct's, 'Diabetic Neuropathic Pain - Pipeline Review, H2 2016', provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
  • The report reviews pipeline therapeutics for Diabetic Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Neuropathic Pain therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathic Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Neuropathic Pain Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Neuropathic Pain - Overview
    • Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis
  • Diabetic Neuropathic Pain - Therapeutics under Development by Companies
  • Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Neuropathic Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Diabetic Neuropathic Pain - Products under Development by Companies
  • Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes
  • Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development
    • APT Therapeutics, Inc.
    • Astellas Pharma Inc.
    • BioDelivery Sciences International, Inc.
    • Bristol-Myers Squibb Company
    • Centrexion Therapeutics Corp
    • Chromocell Corporation
    • Daiichi Sankyo Company, Limited
    • Grunenthal GmbH
    • Hydra Biosciences, Inc.
    • Immune Pharmaceuticals Inc.
    • Laboratorios Del Dr. Esteve S.A.
    • Lohocla Research Corporation
    • Novaremed
    • PeriphaGen, Inc.
    • Pharmaleads SA
    • Prismic Pharmaceuticals, Inc.
    • Relmada Therapeutics, Inc.
    • Sphaera Pharma Pvt. Ltd.
    • Theravasc, Inc.
  • Diabetic Neuropathic Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amitriptyline + ketamine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diclofenac sodium + triclocarban) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APT-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-1069562 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-8464 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cebranopadol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clonidine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNTX-6016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-5026 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GERP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HX-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kindolor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mepivacaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirogabalin besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MR-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRD-135SE1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palmidrol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGN-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-37 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Kv7.2 for Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium nitrite SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Diabetic Neuropathic Pain - Dormant Projects
  • Diabetic Neuropathic Pain - Discontinued Products
  • Diabetic Neuropathic Pain - Product Development Milestones
    • Featured News & Press Releases
      • Mar 04, 2016: BioDelivery Sciences to provide an update on Clonidine Topical Gel at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference
      • Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11
      • Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37
      • Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy
      • Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
      • Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
      • Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
      • Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
      • Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds
      • Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Neuropathic Pain, H2 2016
  • Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by APT Therapeutics, Inc., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Chromocell Corporation, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Novaremed, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by PeriphaGen, Inc., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Pharmaleads SA, H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016
  • Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diabetic Neuropathic Pain - Dormant Projects, H2 2016
  • Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H2 2016
  • Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H2 2016
  • Diabetic Neuropathic Pain - Discontinued Products, H2 2016
  • Diabetic Neuropathic Pain - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Diabetic Neuropathic Pain, H2 2016
  • Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top